

## Harvard Pilgrim Health Care – Pharmacy Prior Authorization Guideline

<b>Guideline Name</b>	<b>DPP-IV Inhibitors:</b> alogliptin, Nesina (alogliptin) and Onglyza (saxagliptin)
-----------------------	--

### 1. Criteria

<b>Product Name:</b> Brand Nesina, generic alogliptin, Brand Onglyza	
Approval Length	24 Month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization/Step Therapy, Non-Formulary
<b>Approval Criteria</b>	
1 - Trial and failure or contraindication to Januvia AND Tradjenta	

<b>Product Name:</b> Brand Nesina, generic alogliptin, Brand Onglyza	
Approval Length	24 Month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization/Step Therapy, Non-Formulary
<b>Approval Criteria</b>	
1 - Patient has experienced improvement while on therapy	

### 2. Background

<b>Benefit/Coverage/Program Information</b>
<p><b>RATIONALE</b> To promote first-line use of the preferred formulary agents Januvia and Tradjenta, prior to the approval of alogliptin, Nesina, or Onglyza.</p> <p><b>FDA APPROVED INDICATIONS</b> JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes mellitus.</p> <p>NESINA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes mellitus.</p> <p>ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes mellitus in multiple clinical settings.</p>

TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus.

**REFERENCES**

- Januvia package insert. Merck & Co., Inc. Whitehouse Station, NJ. June 2019.
- Nesina package insert. Takeda Pharmaceuticals America, Inc. Deerfield, IL. December 2016.
- Onglyza package insert. Bristol-Myers Squibb Company. Princeton, NJ. June 2019.
- Tradjenta package insert. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT. August 2017.

Created: 06/08/12
Revised: 5/20/20 (clarified guideline type to include Step Therapy)
P&T Approval: 12/02/19
Effective: 6/1/20